BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Exemestane readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Exemestane\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07163481-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Exemestane: Phase 1 readout est. (NCT07163481)
DESCRIPTION:Exemestane\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrin
 e Therapy in Patients With HR-positive\, HER2-negative Metastatic Breast C
 ancer Progressed on CDK4/6 Inhibitors\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0716
 3481
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Exemestane: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Brea
 st Cancer\nEstimated primary completion: 30 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364267-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Exemestane: Phase 2 readout est. (NCT06364267)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at 
 High Risk for Breast Cancer.\nEstimated primary completion: 31 January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06364267
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Exemestane: Phase 2 readout est. (NCT02476786)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: Endocrine Treatme
 nt Alone for Elderly Patients With Estrogen Receptor Positive Operable Bre
 ast Cancer and Low Recurrence Score\nEstimated primary completion: 31 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0247
 6786
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Exemestane: Phase 2 readout est. (NCT06179303)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Functional Imaging in Prediction of Response to Abemaciclib for Advanc
 ed Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEstimated prim
 ary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Exemestane: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499999-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Exemestane: Phase 2 readout est. (NCT07499999)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby 
 Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer\nEstimat
 ed primary completion: 31 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07499999
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299890-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Exemestane: Phase 2 readout est. (NCT07299890)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: An Exploratory St
 udy of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exem
 estane as Neoadjuvant Therapy for Triple-Positive Breast Cancer\nEstimated
  primary completion: 1 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07299890
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Exemestane: Phase 2 readout est. (NCT06979596)
DESCRIPTION:Exemestane\, phase 2.\nStudy: A Study of MK-5684 in People With
  Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated primary completio
 n: 4 November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 xemestane#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06979596
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07935317)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: A Study of Tersol
 isib (LY4064809) and Abemaciclib With Hormone Therapies in Participants Wi
 th PIK3CA-Mutated Early Breast Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemestane#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 5317
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Exemestane: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Exemestane\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Exemestane: Phase 3 readout est. (NCT05891093)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Efficacy and Safe
 ty of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SN
 F3-subtype Early Breast Cancer (BCTOP-L-A01)\nEstimated primary completion
 : 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemes
 tane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05891093
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Exemestane: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregio
 nal Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast Ca
 ncer\nEstimated primary completion: 15 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706374-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Exemestane: Phase 1 readout est. (NCT07706374)
DESCRIPTION:Exemestane\, phase 1.\nStudy: E.N.D.E.A.V.O.R.: An Exemestane N
 eeded Dose Efficacy and Verification as an Ovulation Induction Regimen Stu
 dy\nEstimated primary completion: December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07706374
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395336-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07395336)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Meta
 static Breast Cancer and [18F] FES-avid Lesions (COMBINE)\nEstimated prima
 ry completion: December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07395336
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Exemestane: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hy
 droxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbocic
 lib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
 \nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391774-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Exemestane: Phase 3 readout est. (NCT07391774)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Testing Whether H
 ormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by
  Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage 
 Breast Cancer With Low Recurrence Risk\, The RxFINE-Low Trial\nEstimated p
 rimary completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07391774
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Exemestane: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: A Study of Elaces
 trant Versus Standard Endocrine Therapy in Women and Men With ER+\,HER2-\,
  Early Breast Cancer With High Risk of Recurrence\nEstimated primary compl
 etion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 xemestane#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06492616
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Exemestane: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Phase IIIb Study 
 of Ribociclib + ET in Early Breast Cancer\nEstimated primary completion: 7
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exem
 estane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05827081
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937605-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Exemestane: Phase 2 readout est. (NCT07937605)
DESCRIPTION:Exemestane\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: KC1086 in Combination With Fulvestrant for HR-Positive\, HER2-Negative
  Advanced Breast Cancer\nEstimated primary completion: November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/exemestane#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07937605
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Exemestane: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Comp
 ared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in 
 HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\,
  BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 1
 8 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exem
 estane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06380751
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Exemestane: Phase 3 readout est. (NCT05645536)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Safety Extension Study for Subjects With HR+\, HER2- Breast Cancer for
  Subjects Who Have Completed the OVELIA Study\nEstimated primary completio
 n: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exemes
 tane#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05645536
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Exemestane: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Exemestane\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in C
 ombination With Other Antineoplastic Agents in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: July 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04852887-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20310408
DTEND;VALUE=DATE:20310409
SUMMARY:Exemestane: Phase 3 readout est. (NCT04852887)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: De-Escalation of 
 Breast Radiation Trial for Hormone Sensitive\, HER-2 Negative\, Oncotype R
 ecurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)\nEstimated 
 primary completion: 8 April 2031. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04852887
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101159-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07101159)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: Dalpiciclib as Ad
 juvant Therapy for HR-positive/HER2-negative Early-stage Patients\nEstimat
 ed primary completion: December 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07101159
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Exemestane: Phase 2 readout est. (NCT07581834)
DESCRIPTION:Exemestane\, phase 2\, Breast Cancer.\nStudy: Efficacy and Safe
 ty of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/
 HER2- Breast Cancer: a Multicenter\, Prospective Clinical Study\nEstimated
  primary completion: 31 December 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07581834
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223698-9038@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20320502
DTEND;VALUE=DATE:20320503
SUMMARY:Exemestane: Phase 3 readout est. (NCT06223698)
DESCRIPTION:Exemestane\, phase 3\, Breast Cancer.\nStudy: Optimizing Extend
 ed Adjuvant Endocrine Therapy in Patients With Breast Cancer\nEstimated pr
 imary completion: 2 May 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/exemestane#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06223698
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
